A Randomized Open-Label Multi-Centre Active Control Study Investigating the Efficacy and Safety of Imlifidase in Eliminating Donor Specific Anti-HLA Antibodies in the Treatment of Active Antibody-Mediated Rejection in Kidney Transplant Patients
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
